Amylyx Pharmaceuticals Prices Upsized $500 Million Public Offering
Amylyx Pharmaceuticals has priced an upsized public offering of its common stock at $35.50 per share, raising a total gross amount expected to reach approximately $500.2 million before expenses. The company plans to issue 14.09 million shares as part of the underwritten deal. The transaction is set to close on or around August 21, 2026. This offering reflects Amylyx's strategy to raise capital for its ongoing operations and development efforts in pharmaceuticals.
Tickers: $AMLX